Trichomonas vaginalis DNA (T. vaginalis DNA)

Trichomonas vaginalis DNA is the primary molecular target for the nitroimidazole class of antimicrobial agents, which are the standard of care for treating trichomoniasis (StatPearls, 2023). Trichomonas vaginalis is a flagellated protozoan parasite responsible for the most common non-viral sexually transmitted infection worldwide (CDC, 2021). Within the anaerobic environment of the parasite's hydrogenosomes, drugs like metronidazole act as prodrugs that are reduced by electron transport proteins, such as ferredoxin, to form highly reactive nitro radical anions (PubMed: PMC2094731). These radicals interact directly with the parasite's DNA, causing covalent binding and significant strand breakage, which leads to the inhibition of DNA synthesis and eventual cell death (DrugBank, 2024). The detection of specific T. vaginalis DNA sequences using nucleic acid amplification tests (NAAT) is currently the gold standard for clinical diagnosis due to its high sensitivity and specificity (WHO, 2021). However, the increasing prevalence of clinical resistance, often involving altered metabolic activation of the drugs, remains a significant therapeutic challenge (PubMed: PMC3442844).

Other names

Trichomonad DNAT. vaginalis genomic DNATrichomonas vaginalis genome

Reductive activation of nitroimidazole prodrugs by parasite enzymes into reactive nitro radical intermediates that cause oxidative DNA strand breakage and inhibition of nucleic acid synthesis (StatPearls, 2023).